Illumina, Inc. (NASDAQ:ILMN) and Everpure, Inc. (NYSE:P) are set to join the S&P 500 as part of the index’s quarterly rebalancing, with the changes taking effect before the market opens on September 21. Both companies will replace Builders FirstSource and The Trade Desk. Both companies are moving up from the S&P MidCap 400. The change […]

The iShares Biotechnology ETF (IBB) surged 26% over three months ending September 4, 2026, outperforming the S&P 500's 4% gain by 22 points. This rally is driven by big pharmaceutical companies acquiring mid- and small-cap biotech firms to offset revenue losses from expiring drug patents, known as the patent cliff. IBB focuses on established biotech firms, with top holdings like Vertex and Amgen, making it a less volatile option than smaller clinical-stage biotech ETFs. While the sector has rebounded sharply, investors should consider the high entry price and potential risks like clinical trial failures and drug pricing policy changes before adding exposure.

Biotech just staged one of its sharpest reversals in years, and whether you caught it or completely missed it, the same uncomfortable question now sits in front of every portfolio: does the trade still have teeth, or did the easy money already leave?

Biotech just staged one of its sharpest reversals in years, and whether you caught it or completely missed it, the same uncomfortable question now sits in front of every portfolio: does the trade still have teeth, or did the easy money already leave?

NRG Energy gained 6.4% and Constellation Energy rose 4.9% on September 4 while the S&P 500 fell 0.4%. The gains were consistent with the broader AI-power trade where data-center projects increasingly depend on generators that can add reliable capacity, navigate interconnection queues, and sign contracts before construction. NRG Energy, Inc. (NYSE:NRG) and Constellation Energy Corporation […]

Dell is the S&P 500’s third-best stock in 2026 after a 316% rally, with a $95B AI backlog and S&P 100 promotion reinforcing the surge.

The Nasdaq 100, Dow Jones and S&P 500 remain supported despite choppy consolidation and rising rates. Key technical levels include Dow support near 53,000 and an S&P 500 range between 7,600 support and 7,800 resistance.

S&P; 500 Inclusion: Social media buzz centers on Bloom Energy's addition to the S&P; 500, which many

While PACCAR has outpaced the S&P 500 Index over the past year, analysts are cautiously optimistic about the stock’s prospects.

Monster Beverage has rallied the S&P 500 Index over the past year, and analysts remain somewhat bullish about the stock’s growth prospects.

The S&P 500 dropped after the strong NFP report pushed rate hike expectations higher. The US CPI is now the next key catalyst to focus on. Soft or in-line…

Investors waiting for a market pullback may have reached one of the best buying opportunities of the year in the S&P 500.

The S&P 500 CAPE ratio is a useful valuation tool to determine whether the market is expensive or fairly priced.

Tyler Technologies has yet to recover from the tumble it took when "SaaSpocalypse" fears swamped the software sector.

S&P 500 defensive sectors (staples, health care, utilities) are near an all-time low 15% market-cap weight.